About us

James Cook is the Founder of Evergreen Theragnostics and serves as President and Chief Executive Officer.

Prior to Evergreen, James was General Manager for the US business of Advanced Accelerator Applications (AAA), from 2014-2019. During his tenure there, his team successfully launched the first commercial Ga 68 based product in the US, Netspot, and the first commercial Lu-177 based product, Lutathera. He also oversaw the build-out of AAA’s Millburn, NJ factory, and built the AAA US organization from its inception.

James originally entered the radiopharmaceutical industry from management consulting in 2005 with Siemens Healthineers Molecular Imaging (SHMI). He served as Sr. Director of Strategy for SHMI, based in Chicago, IL, and later as VP Sales and Business Development at PETNET Solutions, a subsidiary of SHMI based in Knoxville, TN.

James received his MBA from INSEAD in Fontainebleau, France, and previously Bachelor of Science degrees in Mechanical and Electrical Engineering from Kettering University in Flint, MI

Alex serves as the Chief Financial Officer, with responsibility for all financial aspects of the business including accounting, finance, tax reporting, and investor relations.

Alex has more than 10 years of experience spanning both the banking and pharmaceutical industry. Alex began his career at KPMG in the financial services audit practice, serving publicly traded banks, broker dealers, and financial technology companies. Prior to Evergreen, Alex served as the VP, Controller of Blue Foundry Bancorp, a $2 billion community bank in NJ.

Alex oversaw the accounting department through the Bank’s IPO in 2021, and post-IPO served as the Interim-CFO for nearly a year. Alex is a licensed CPA in New Jersey, and a member of the AICPA and NJCPA. Alex has a Bachelor of Science and Master of Science degree from Liberty University,

Tom Reiner, PhD serves as the Chief Scientific Officer at Evergreen Theragnostics. At Evergreen, Tom oversees the preclinical and clinical development of novel radiotherapeutic agents. Together with his team, he seeks to conceive and develop novel radiolabeled vectors, in order to visualize and treat some of the most devastating malignancies.

Prior to Evergreen, Tom was the Executive Director and Radioligand Therapy Lead, at the Novartis Institutes for Biomedical Research (NIBR). Tom also served as Head, Radioligand Therapy Drug Discovery for Advanced Accelerator Applications (AAA), a Novartis Company. He was also a member of the AAA Executive Leadership Team, and a member of the Sloan Kettering Institute Chemical Biology Program.

Tom had also served as an Associate Member and Laboratory Head at Memorial Sloan Kettering Cancer Center (from 2012 to 2021). He held affiliations as an Associate Professor at Gerstner Sloan Kettering Graduate School of Biomedical Sciences and as Associate Professor at Weill Cornell Medical College.Tom received his Ph.D. from the Technical University of Munich in Germany.

Dipesh Patel is responsible for legal, compliance, litigation, and transactional functions.

Dipesh has served as our General Counsel since May 2023. Dipesh supports Evergreen’s commercial, compliance, and regulatory operations to align with Evergreen’s legal strategies to ensure solutions to assist Evergreen in achieving its business and development objectives. Prior to joining Evergreen, Dipesh served as general counsel for Rising Pharmaceuticals. Mr. Patel started his legal career practicing restructuring and insolvency law. Dipesh holds a Bachelor of Arts from Seton Hall University and a Juris Doctor degree from Rutgers University.

Alison serves as the VP, Head of Human Resources for Evergreen since joining in November of 2022. Her experience in HR began in recruiting in ecommerce and consulting leading to partnership and leadership roles in Financial Services and Asset Management in a large corporate environment. After leaving corporate asset management she moved into a startup consulting company firm as Senior Director, building out the people and culture of the company alongside the founders and contributing to the successful acquisition of the firm. From there she stayed with the challenges of running HR in small company start up environments, both at a private insurance company and a Healthcare service company before joining Evergreen.

Alison has her BA in Political Science and her Senior HR Professional (SPHR) accreditation with the Human Resources Certification Institute. In her spare time, she likes to rescue and feed all animals, coach CrossFit, and spend time with her family.

Kyle serves as the VP of Manufacturing at Evergreen Theragnostics. In this role, he oversees the daily operations of the Springfield Manufacturing Facility and works to ensure the consistent and timely production of high-quality radiopharmaceuticals at all stages of the product lifecycle. He also serves as the site Radiation Safety Officer, administering the radiation safety program for all personnel.

Prior to Evergreen Theragnostics, Kyle was a Facility Manager and Radio pharmacist for SOFIE, where he managed a cyclotron radiopharmacy site manufacturing Fluorine-18 labeled radiopharmaceuticals. He was also a Pharmacy Manager at a CVS Health pharmacy.

He has a Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Health Sciences University and is pursuing a degree in Radiation Health Physics.

Serge Lyashchenko is one of the co-founders of Evergreen Theragnostics and a valued advisor, as well as a radio pharmacist at Memorial Sloan Kettering in NYC, specializing in the development of immunoPET and Theranostics agents. With over ten years of experience in radiopharmacy, he focuses on safely using radiation to treat various diseases. His work involves supervising the manufacturing of novel molecular imaging agents at MSK’s state-of-the-art Radiochemistry and Molecular Imaging Probe Core Facility. Additionally, Dr. Lyashchenko actively collaborates with both academic and industry colleagues on early agent development strategies. These efforts aim to move new agents beyond first-in-human studies and potentially establish them as standard care in the future. He is a member of several committees, including the Investigation New Drug Committee, Radiology Quality Assurance Committee, Committee on Radiation, and Radioactive Drug Research Committee. His goal is to contribute to providing the best cancer care through efficient and controlled development of molecular imaging agents.

Dr. Lyashchenko’s educational background includes a PharmD from the Ernest Mario School of Pharmacy, Rutgers University.

James Cook is the Founder of Evergreen Theragnostics and serves as President and Chief Executive Officer.

Prior to Evergreen, James was General Manager for the US business of Advanced Accelerator Applications (AAA), from 2014-2019. During his tenure there, his team successfully launched the first commercial Ga 68 based product in the US, Netspot, and the first commercial Lu-177 based product, Lutathera. He also oversaw the build-out of AAA’s Millburn, NJ factory, and built the AAA US organization from its inception.

James originally entered the radiopharmaceutical industry from management consulting in 2005 with Siemens Healthineers Molecular Imaging (SHMI). He served as Sr. Director of Strategy for SHMI, based in Chicago, IL, and later as VP Sales and Business Development at PETNET Solutions, a subsidiary of SHMI based in Knoxville, TN.

James received his MBA from INSEAD in Fontainebleau, France, and previously Bachelor of Science degrees in Mechanical and Electrical Engineering from Kettering University in Flint, MI

Serge Lyashchenko is one of the co-founders of Evergreen Theragnostics and a valued advisor, as well as a radio pharmacist at Memorial Sloan Kettering in NYC, specializing in the development of immunoPET and Theranostics agents. With over ten years of experience in radiopharmacy, he focuses on safely using radiation to treat various diseases. His work involves supervising the manufacturing of novel molecular imaging agents at MSK’s state-of-the-art Radiochemistry and Molecular Imaging Probe Core Facility. Additionally, Dr. Lyashchenko actively collaborates with both academic and industry colleagues on early agent development strategies. These efforts aim to move new agents beyond first-in-human studies and potentially establish them as standard care in the future. He is a member of several committees, including the Investigation New Drug Committee, Radiology Quality Assurance Committee, Committee on Radiation, and Radioactive Drug Research Committee. His goal is to contribute to providing the best cancer care through efficient and controlled development of molecular imaging agents.

Dr. Lyashchenko’s educational background includes a PharmD from the Ernest Mario School of Pharmacy, Rutgers University.